Deck the halls with more appointments in the last Peer Review for 2021. Thanks for reading every week!
Joan Shen? When the calendar flips to 2022, Joan Shen is out at I-Mab “to pursue other interests,” leaving founder and chairman Jingwu Zang to succeed her as acting CEO in a bit of a surprise. Under Shen’s leadership, I-Mab formed a CD47 alliance with AbbVie in September 2020 with lemzoparlimab as the centerpiece, and a year later our Amber Tong detailed I-Mab’s aspirations for other comparable partnerships, notably for development of the CD73 antibody uliledlimab. Shen was one of our 20 Women in Biopharma R&D honorees this month.
Elsewhere at I-Mab, Andrew Zhu — formerly a member of the Chinese biotech’s scientific advisory board — has been named president and will lead global R&D efforts. He also grabs a…
Click here to view original post
